Risk Factors for Cranial Ischemic Complications in Giant Cell Arteritis
- 1 March 2004
- journal article
- review article
- Published by Wolters Kluwer Health in Medicine
- Vol. 83 (2) , 114-122
- https://doi.org/10.1097/01.md.0000119761.27564.c9
Abstract
Cranial ischemic complications (CICs) are among the presenting manifestations of giant cell arteritis (GCA). Yet patients with GCA may develop CICs at a later stage, despite steroid therapy. In the current report we delineate risk factors for CICs, both at presentation and during follow-up, and review the relevant literature. We reviewed charts of 175 patients with GCA. Follow-up data were available for 166 patients. CICs at presentation or developing within 2 weeks of GCA diagnosis were considered GCA related. CICs developing later were considered GCA related only when associated with other GCA-related manifestations or acute-phase reactions. Associations between CICs and other variables were tested by multivariate analysis. At presentation, 43 patients (24.6%) had CICs. Risk factors were transient cerebro-ophthalmic ischemic episodes (COIEs) (odds ratio [OR] 4.3) and male sex (OR 2.5), while the presence of systemic symptoms was "protective" (OR 0.3). During follow-up 8.4% of patients with GCA developed new CICs. Risk factors in these cases were previous CICs at presentation (OR 5.6) and transient COIEs developing during follow-up (OR 14.8). The use of low-dose aspirin was protective (OR 0.2). These data, together with data from the literature review, suggest that GCA patients with transient COIEs and without fever or other systemic symptoms are at increased risk of presenting with CICs. Risk factors for late-developing CICs were CICs at presentation and late-developing transient COIEs.Keywords
This publication has 25 references indexed in Scilit:
- Acute systemic inflammation enhances endothelium-dependent tissue plasminogen activator release in menJournal of the American College of Cardiology, 2003
- Tissue and Serum Angiogenic Activity Is Associated With Low Prevalence of Ischemic Complications in Patients With Giant-Cell ArteritisCirculation, 2002
- Antiphospholipid antibodies and thrombophilic factors in giant cell arteritisSeminars in Arthritis and Rheumatism, 2001
- Scalp necrosis with giant cell arteritisOphthalmology, 1998
- Anticardiolipin antibodies and giant cell arteritis: A prospective, multicenter case-control studyArthritis & Rheumatism, 1998
- Association between strong inflammatory response and low risk of developing visual loss and other cranial ischemic complications in giant cell (temporal) arteritisArthritis & Rheumatism, 1998
- Clinical features in patients with permanent visual loss due to biopsy- proven giant cell arteritisRheumatology, 1997
- Visual Prognosis in Giant Cell ArteritisPublished by Elsevier ,1993
- Thrombocytosis and ischaemic complications in giant cell arteritis.BMJ, 1991
- Neurologic disease in biopsy‐proven giant cell (temporal) arteritisNeurology, 1988